Overview: 45 CFR 46.111 (a)(2) states, In evaluating risks and benefits, the IRB should consider only those risks and benefits that may result from the research (as distinguished from risks and benefits of therapies subjects would receive even if not participating in the research). How the study is designed can minimize potential risks to participants. Studies that are deemed minimal risk have greater options when it comes to using an expedited review system and options for consent.

Date : 8th October 2014 to 8th October 2014

Place : United States, Online event

Website :http://bit.ly/1pjhCAe

Contact Person:Roger Steven

Description:

Overview: 45 CFR 46.111 (a)(2) states, "In evaluating risks and benefits, the IRB should consider only those risks and benefits that may result from the research (as distinguished from risks and benefits of therapies subjects would receive even if not participating in the research)." How the study is designed can minimize potential risks to participants. Studies that are deemed "minimal risk" have greater options when it comes to using an expedited review system and options for consent.

Overview: 45 CFR 46.111 (a)(2) states, In evaluating risks and benefits, the IRB should consider only those risks and benefits that may result from the research (as distinguished from risks and benefits of therapies subjects would receive even if not participating in the research). How the study is designed can minimize potential risks to participants. Studies that are deemed minimal risk have greater options when it comes to using an expedited review system and options for consent. will be held in Online event,United States on date 2014-10-08

---

Deadline for abstracts/proposals : 7th October 2014

Keynote Speakers :

Check the event website for more details.